Vanda Pharmaceuticals (VNDA) and AnaptysBio (ANAB) said Monday that they signed an agreement providing Vanda an exclusive global license to develop, manufacture, and commercialize imsidolimab.
As part of the agreement, Vanda will make an upfront payment of $10 million and an additional $5 million for the existing drug supply to AnaptysBio, which is also eligible for up to $35 million in milestone payments and a 10% royalty on net sales, according to a joint statement.
Two phase 3 trials assessing the safety and efficacy of imsidolimab in generalized pustular psoriasis have been completed, the companies said.
Vanda plans to complete technology transfer activities in 2025, the companies added.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。